New study finds improved vaccine that protects against nine types of HPV

Cervical cancer is the second most common cause of cancer-related death worldwide, with almost 300,000 deaths occurring each year. More than 80 percent of these deaths occur in developing nations. The advent of human papillomavirus (HPV) vaccines has significantly reduced the number of those who develop and die from cervical cancer. And thanks to an international effort to improve the vaccine, the medical community is one step closer to preventing more HPV-associated diseases. The researchers, including those from Moffitt Cancer Center, published the final results of a study showing the newest vaccine is highly effective at preventing HPV infection and disease. The study was published this week in The Lancet.

HPV is an extremely common virus. It is estimated that by age 50, four out of five women have been infected with the virus at one point throughout their lifetimes. HPV causes ailments such as genital and anal warts and, in some instances, continued infection can lead to the development of benign or cancerous growths of the cervix, vulva, vagina, anus, penis, tonsils, and base of the tongue. There are more than 100 types of HPV, but only approximately 13 types are associated with cancer development. HPV 16 and 18 alone are estimated to cause 70 percent of all cervical cancers.

Two existing HPV vaccines, Cervarix® and Gardasil®, are effective at preventing disease caused by HPV types 16 and 18, while Gardasil also protects against genital warts caused by HPV 6 and 11. However, these vaccines do not protect against all HPV types that are associated with cancer. Scientists developed an improved vaccine called 9vHPV that targets HPV 16, 18, 6, and 11, and an additional 5 HPV types that are the next most commonly associated with cervical cancer (HPV 31, 33, 45, 52 and 58).

"Based on epidemiological studies, the 9vHPV vaccine could prevent approximately 90 percent of cervical cancer, 90 percent of HPV-related vulvar and vaginal cancer, 70 to 85 percent of high-grade cervical disease in females, and approximately 90 percent of HPV-related anal cancer and genital warts in males and females worldwide," explained Anna R. Giuliano, Ph.D., Director of the Center for Infection Research in Cancer at Moffitt.

Researchers from 18 countries and 105 study sites conducted a phase 3 study to compare the activity of the new 9vHPV vaccine against the older vaccine that protected against four HPV types (Gardasil). The study randomized 14,215 women 16 to 26 years of age to either 9vHPV or Gardasil, and the study participants were medically followed for 6 years after vaccination.

The study found that the 9vHPV vaccine has long-term activity against HPV infection and disease. The 9vHPV vaccine reduced the risk of developing HPV 31/33/45/52/58-related cervical, vulvar, and vaginal disease by 97.7 percent when compared to Gardasil®, and the two vaccines had similar activity at preventing HPV 6/11/16/18-associated disease. The 9vHPV vaccine was also highly effective at reducing the risk of having HPV 31/33/45/52/58-associated cervical cell abnormalities, biopsies, and definitive therapies.

9vHPV, known as Gardasil 9, became available in 2015 to protect females and males ages 9 through 26 years against HPV-associated cancers and genital warts. Scientists hope its continued use will greatly reduce the incidence and mortality of HPV-associated diseases.

"The 9vHPV vaccine is licensed in over 40 countries for the prevention of HPV-related anogenital cancers and pre-cancer, and genital warts. The results of this study support comprehensive vaccination programs and inform public health decision related to implementation," said Giuliano.

Warner K Huh, Elmar A Joura, Anna R Giuliano, Ole-Erik Iversen, Rosires Pereira de Andrade, Kevin A Ault, Deborah Bartholomew, Ramon M Cestero, Edison N Fedrizzi, Angelica L Hirschberg, Marie-Hélène Mayrand, Angela Maria Ruiz-Sternberg, Jack T Stapleton, Dorothy J Wiley, Alex Ferenczy, Robert Kurman, Brigitte M Ronnett, Mark H Stoler, Jack Cuzick, Suzanne M Garland, Susanne K Kjaer, Oliver M Bautista, Richard Haupt, Erin Moeller, Michael Ritter, Christine C Roberts, Christine Shields, Alain Luxembourg.
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial.
The Lancet, 5 September 2017, doi: 10.1016/S0140-6736(17)31821-4.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Soy lecithin NSAID combo drug protects against can…

When scientists at The University of Texas Health Science Center at Houston (UTHealth) applied a chemical found in soybeans to a non-steroidal anti-inflammatory drug (NSA...

Novartis receives positive CHMP opinion for Aimovi…

Novartis announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for Aimovig® (erenumab) for t...

FDA takes action against 53 websites marketing una…

The U.S. Food and Drug Administration today announced that it has warned nine online networks, operating a total of 53 websites, that they must stop illegally marketing p...